Stockscreener 앱 받기
2.28
9.62%
0.20
시간 외 거래:
2.33
0.05
+2.19%
전일 마감가:
$2.08
열려 있는:
$2.06
하루 거래량:
83,215
Relative Volume:
0.10
시가총액:
$12.87M
수익:
$4.19M
순이익/손실:
$-11.51M
주가수익비율:
-0.0129
EPS:
-177.3844
순현금흐름:
$-3.05M
1주 성능:
-3.80%
1개월 성능:
-17.09%
6개월 성능:
-63.43%
1년 성능:
+0.00%
1일 변동 폭
$2.06
$2.405
1주일 범위
$2.02
$2.5257
52주 변동 폭
$1.75
$12.87
Vyome Holdings Inc Stock (HIND) Company Profile
명칭
Vyome Holdings Inc
전화
949-429-6680
주소
1001 CALLE AMANECER, SAN CLEMENTE
Compare HIND vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HIND
Vyome Holdings Inc
|
2.28 | 11.74M | 4.19M | -11.51M | -3.05M | -177.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vyome Holdings Inc 주식(HIND)의 최신 뉴스
Vyome Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Vyome 10-K: $0.32M Revenue, $(4.86) Loss per Share - TradingView
Vyome (HIND) versus Its Competitors Critical Analysis - Defense World
Head-To-Head Comparison: Vyome (HIND) versus The Competition - Defense World
Vyome (HIND) vs. Its Rivals Head to Head Contrast - Defense World
Vyome (HIND) & The Competition Head to Head Analysis - Defense World
Reviewing Vyome (HIND) and Its Rivals - Defense World
HIND Technical Analysis & Stock Price Forecast - Intellectia AI
RSLS SEC FilingsReShape Lifesciences Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Vyome (HIND) versus Its Rivals Financial Analysis - Defense World
Analyzing Vyome (HIND) & Its Peers - Defense World
Vyome (HIND) & Its Peers Financial Survey - Defense World
Critical Comparison: Vyome (HIND) versus The Competition - Defense World
Financial Contrast: Vyome (HIND) & The Competition - Defense World
HIND Should I Buy - Intellectia AI
Vyome’s Livechain Acquires Humanyze to Expand AI HR Analytics - TipRanks
Vyome Holdings Unit LiveChain to Acquire $5.8M Humanyze Notes, Issuing 25% Equity to Remus - TradingView
Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company - 01net
Livechain completes acquisition of senior, secured debt of Humanyze - marketscreener.com
Analyzing Vyome (HIND) and Its Competitors - Defense World
Reviewing Vyome (HIND) and The Competition - Defense World
Head to Head Review: Vyome (HIND) and Its Rivals - Defense World
Comparing Vyome (NASDAQ:HIND) and Nanovibronix (NASDAQ:FEED) - Defense World
Reviewing Vyome (HIND) & The Competition - Defense World
Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity - Bluefield Daily Telegraph
Critical Survey: Vyome (HIND) & Its Competitors - Defense World
Vyome (HIND) versus Its Competitors Financial Analysis - Defense World
Analyzing Vyome (HIND) & Its Competitors - Defense World
Vyome Reports Positive Phase 2 Data for VT-1953 Gel - TipRanks
Vyome Holdings, Inc. Reports Positive Phase 2 Results for VT-1953 - TradingView
Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months - The Joplin Globe
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Vyome raises $5.29 million to fund phase 3 trial of MFW treatment - Investing.com Nigeria
Vyome raises $5.29 million to fund phase 3 trial of MFW treatment By Investing.com - Investing.com South Africa
Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results - BioSpace
Vyome capitalizes all VT-1953 funding requirements for initial phase 3 results - marketscreener.com
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Penny Stocks To Follow Now – January 27th - Defense World
Recommendations-Union Budget FY27, Vyome Holdings, Inc. - Medical Buyer
Vyome Holdings Highlights VT-1953 Market Potential Analysis - TipRanks
Vyome Holdings, Inc Announces Key Findings on VT-1953 - TradingView
Vyome Holdings Stock Tumults After Strategic Moves in Europe - timothysykes.com
Hindustan Diverges: Financial Snapshot Paints Varied Picture - StocksToTrade
Vyome Holdings Eyes Growth Amid Market Turbulence - timothysykes.com
Vyome stock soars after analyst values lead drug candidate at $1 billion - Investing.com Canada
Independent Analyst Values Vyome’s VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study - Business Wire
Vyome (NASDAQ:HIND) and Medline (NASDAQ:MDLN) Critical Survey - Defense World
“Malignant fungating wounds remain significantly under-recognised and under-treated in India” - BioSpectrum India
HIND Forecast — Price Prediction for 2026. Should I Buy HIND? - Intellectia AI
MarketsMedicine Hat NewsMedicine Hat NewsVyome Holdings, Inc.Common Stock (Nasdaq:HIND) Stock Quote - FinancialContent
Vyome’s LiveChain signs LOI for Humanyze note acquisition - MSN
Vyome Holdings Inc (HIND) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):